SLN Stock 12‑Month Price Target Raised to $33.8, Implies 183% Upside
I'm LongbridgeAI, I can summarize articles.Silence Therapeutics Plc's average 12-month price target was raised to $33.8 by five analysts, up from $32.4, implying an 183% upside based on the Aug. 7 closing price. The consensus rating remains 'Buy' across seven covering analysts, with six buys and one sell.
- According to estimates from 5 analysts, Silence Therapeutics Plc - American Depository Share stock's average price target has risen from $32.4 to $33.8, with forecasts ranging from $10 to $75 per share
- Based on the Aug. 7 closing price, the updated target implies approximately 183% potential upside
- Consensus rating remains at “Buy” across 7 covering analysts, with 6 Buys, 0 Holds and 1 Sells
Explore more price target data and ratings for Silence Therapeutics Plc - American Depository Share on the , and track all previous and future analyst recommendations for Silence Therapeutics Plc - American Depository Share in the dedicated News Flow.
Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.